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Angiotensin II vaccination lowers 
blood pressure in patients with 
hypertension
Hypertension can be controlled with existing drugs such as angi-
otensin-converting enzyme inhibitors or angiotensin II recep-
tor blockers. However, success is limited because many patients 
do not adhere to treatment. Immunizing these patients against 
angiotensin II provides another treatment option. Tissot et al. 
investigated the safety and eﬃcacy of CYT006-AngQb, a vaccine 
based on a virus-like particle that targets angiotensin II to reduce 
ambulatory blood pressure. In the double-blind, randomized, 
placebo-controlled trial, 72 patients with mild-to-moder-
ate hypertension received subcutaneous injections of 100 µg 
CYT006-AngQb, 300 µg CYT006-AngQb, or placebo, at 0, 4, 
and 12 weeks. Twenty-four-hour ambulatory blood pressure 
was measured before treatment and at 14 weeks. Five serious 
adverse events were reported (two in the 100 µg group, two 
in the 300 µg group, and one in the placebo group); none was 
deemed to be treatment related. Most side eﬀects were mild, 
with transient reactions at the injection site. Mild, transient 
inﬂuenza-like symptoms were seen in three patients in the 
100 µg group, seven in the 300 µg group, and none in the pla-
cebo group. In the 300 µg group, a reduction from baseline was 
seen in mean ambulatory daytime blood pressure 14 weeks 
later by −9.0/−4.0 mm Hg compared with placebo (P = 0.015 
for systolic and 0.064 for diastolic). The 300 µg dose reduced 
early-morning blood-pressure surge compared with placebo 
(change at 0800 hours −25/−13 mm Hg; P < 0.0001 for systolic, 
P = 0.0035 for diastolic). The immunizations were associated 
with no serious adverse events. The authors conclude that the 
300 µg dose reduced blood pressure in patients with mild-to-
moderate hypertension during the daytime, especially in the 
early morning. A vaccination treatment regimen would require 
a few injections per year, when the vaccine could be adminis-
tered during regular doctor visits. While vaccinations would 
likely improve treatment, the treatment needs to be supported 
by clinical data showing eﬃcacy and safety in a larger hyperten-
sive population. (Lancet 2008; 371: 821–827; doi:10.1016/S0140-
6736(08)60381-5)
Marc De Broe
Catecholamines regulate renalase
Patients with advanced chronic kidney disease (CKD) have 
increased plasma catecholamines due to increased sympathetic 
nerve activity and decreased catecholamine clearance. Renalase, 
a recently identiﬁed amine oxidase, is secreted into the blood 
by the kidneys and metabolizes circulating catecholamines. It 
is a 342-amino acid protein, a distant relative of monoamine 
oxidase-A that has been very well conserved throughout evo-
lution. In vivo, renalase lowers blood pressure by decreasing 
cardiac contractility and heart rate and preventing the expected 
compensatory increase in peripheral vascular tone. The pro-
tein can be detected in human plasma by immunoblotting. Its 
concentration is markedly reduced in patients with end-stage 
renal disease, suggesting that the kidneys are its major source. 
Renalase deﬁciency in CKD may contribute to the increased 
catecholamine levels observed in this condition and thus to 
the heightened sympathetic activity of end-stage renal disease 
patients. In a recent study, Li et al. examined the role of renalase 
in maintaining catecholamine homeostasis in vivo. They found 
that under basal conditions plasma renalase activity was unde-
tectable, likely because of the presence of an uncharacterized 
inhibitor in plasma. However, within 1 minute of the adminis-
tration of epinephrine or dopamine, renalase activity increased 
signiﬁcantly, and it remained high long after the catecholamine 
infusion was terminated; this indicates that acute increases in 
plasma catecholamines induced a rapid and sustained increase 
in blood renalase activity. Analysis of epinephrine-mediated 
hemodynamic changes in normotensive rats showed that inac-
tive renalase became maximally activated when systolic pressure 
increased by more than 5 mm Hg. The increase in catecho-
lamines also increased plasma renalase concentration. In vitro, 
cells exposed to dopamine upregulated steady-state renalase 
gene expression more than tenfold. Finally, activation of plasma 
renalase was found to be abnormal in rats with CKD (Figure). 
These interesting studies identify a novel mechanism for the 
regulation of circulating catecholamines. Excess plasma cat-
echolamines induce activation of inactive renalase, while active 
enzyme degrades catecholamines. Excess catecholamines not 
only activate the enzyme but also promote its secretion and syn-
thesis. Because CKD is associated with systemic abnormalities 
that may derive from sympathetic hyperactivity such as cardiac 
hypertrophy and hypertension, renalase replacement may be an 
attractive therapeutic avenue. (Circulation 2008; 117: 1277–1282; 
doi:10.1161/CIRCULATIONAHA.107.732032)
Juan Oliver
Renal renalase decreased in chronic kidney disease. Immunocytochemical 
staining with antibody to renalase (red) and nuclear staining (blue) in 
kidneys of normal rats and rats with five-sixths nephrectomy (5/6 Nx).
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The Notch pathway in podocytes is 
involved in glomerular diseases and 
proteinuria
Podocyte dysfunction has been implicated in the pathogen-
esis of several glomerular diseases, such as focal segmental 
glomerulosclerosis (FSGS), diabetic nephropathy (DNP), and 
glomerulosclerosis caused by inherited mutations of podocyte-
speciﬁc proteins. Fewer podocytes per glomerulus has been 
associated with greater albuminuria and faster progression to 
renal failure. The Notch signaling pathway comprises a fam-
ily of transmembrane receptors, their ligands, negative and 
positive modiﬁers, and transcription factors. Binding of ligand 
renders the Notch receptor susceptible to metalloprotease- and 
γ-secretase-mediated proteolytic cleavage, which results in 
the release of the Notch intracellular domain (ICN) from the 
plasma membrane and its subsequent translocation into the 
nucleus. Once there, ICN associates with other DNA-binding 
proteins, including Rbpj, to form heteromeric complexes that 
mediate transcription of target genes. The Notch pathway is 
crucial in podocyte development; deletion of the Notch2 or 
presenilin gene (presenilins share redundant activities in Notch 
processing and signaling) or treatment of developing kidney 
explants with a γ-secretase inhibitor gives rise to nephrons 
without glomeruli and proximal tubules. Furthermore, Notch1 
activity is very high during kidney development but very mini-
mal in the mature kidney. Niranjan et al. now report that the 
Notch pathway is activated de novo in the glomeruli (mainly in 
podocytes) of humans with DNP and FSGS (Figure) and in the 
glomeruli of rodents with similar diseases. More interestingly, 
they found that de novo expression of Notch1 in podocytes was 
suﬃcient to induce proteinuria and glomerulosclerosis in mice, 
with a pattern that was similar to that of FSGS of humans. They 
also found that genetic deletion of the Notch transcriptional 
partner Rbpj in podocytes or pharmacological inhibition of 
the Notch pathway (with a γ-secretase inhibitor) protected 
rats with proteinuric kidney diseases. γ-secretase inhibition 
not only prevented the development of albuminuria but also 
signiﬁcantly lowered established albuminuria. These results are 
consistent with microarray studies in DNP showing increased 
Notch1 and downstream target gene expression and suggest 
a new mechanism for the pathogenesis of albuminuria and 
glomerulosclerosis. Finally, they suggest the possibility that 
the Notch pathway might be a candidate for pharmacological 
intervention in glomerular disease. (Nat Med 2008; 14: 
290–298; doi:10.1038/nm1731)
Juan Oliver
Intrinsic epithelial cells repair injury 
of kidney epithelia
Acute kidney injury can cause widespread apoptosis, necrosis, and 
loss of kidney function. However, because of the kidney’s capac-
ity for repair, recovery of renal function is possible. The cellular 
hallmark of kidney repair is a rapid proliferative response, which 
ultimately leads to restoration of nephron structure and function. 
The origins of the cells that replace injured tubular epithelia are 
not known, but several recent studies suggest an intrarenal source. 
Adult, organ-speciﬁc stem cells are implicated in both homeostatic 
tissue maintenance and functional restoration after injury in several 
organs, but it is not yet clear whether the kidney harbors similar 
stem cells. Using genetic fate-mapping techniques, Humphreys et 
al. generated transgenic mice in which 94%–95% of the tubular 
epithelial cells, but no interstitial cells, were labeled with either 
β-galactosidase (lacZ) or red ﬂuorescent protein (RFP). Two days 
after ischemia–reperfusion injury (IRI), approximately 50% of outer 
medullary epithelial cells expressed both RFP and Ki67 (a marker 
of cell proliferation), indicating that diﬀerentiated epithelial cells 
that survived injury underwent proliferative expansion (Figure). To 
quantitate cell proliferation in the postischemic kidney, investiga-
tors administered 5-bromodeoxyuridine (BrdU) after unilateral IRI 
and found that in the injured kidney approximately 70% of the epi-
thelial cells had incorporated BrdU, compared with approximately 
4% of cells in the uninjured kidney. Despite this extensive cell pro-
liferation, no dilution of either cell-fate marker was observed after 
repair. By genetically labeling renal interstitial cells, investigators 
found that these cells did not contribute to renal epithelia after renal 
repair. Such elegant results indicate that regeneration by surviving 
tubular epithelial cells is the predominant mechanism of repair after 
ischemic tubular injury in the adult mammalian kidney. (Cell Stem 
Cell 2008; 2: 284–291; doi:10.1016/j.stem.2008.01.014)
Juan Oliver
Immunodetection of the intracellular domain of Notch1 in samples from 
normal subjects, subjects with diabetic nephropathy (DNP), and subjects 
with focal segmental glomerulosclerosis (FSGS).
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In mice subjected to unilateral ischemia–reperfusion injury (IRI), injured 
epithelial cells can be seen 2 days after IRI (top). Ki67-positive cells are rarely 
observed in the uninjured kidney in either cortex (middle) or medulla 
(right), whereas numerous intratubular Ki67 (green, nucleus) and RFP (red) 
double-positive cells are seen in 2-day-postischemic kidney.
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